8-K: 374Water Inc. Notifies Nasdaq of Non-Compliance with Independent Director Requirement

374Water Inc. reports non-compliance with Nasdaq's independent director requirement and is granted a cure period to regain compliance.

Summary

• 374Water Inc. has notified Nasdaq that it no longer meets the independent director requirement as per Nasdaq Listing Rule 5605(b)(1).
• Nasdaq has granted the company a cure period to regain compliance, expiring on the earlier of the next annual meeting or March 9, 2026, or September 8, 2025, if the annual meeting is before that date.
• The company intends to appoint an additional independent director before the cure period expires.
• The notification does not immediately affect the listing or trading of the company's common stock on the Nasdaq Capital Market under the symbol SCWO.
• The company plans to hold its 2025 Annual Meeting of Stockholders on June 11, 2025.
• Stockholders intending to bring a proposal to the 2025 Annual Meeting must notify the company by April 12, 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company is non-compliant, they are taking steps to address the issue and have been granted a cure period. There is uncertainty regarding their ability to regain compliance.

Positives

• Nasdaq has granted a cure period for 374Water Inc. to regain compliance with the independent director requirement.
• The company intends to appoint an additional independent director, indicating a proactive approach to resolving the non-compliance issue.
• The non-compliance notification does not immediately affect the listing or trading of the company's stock.

Negatives

• 374Water Inc. is currently not in compliance with Nasdaq Listing Rule 5605(b)(1).
• There is no assurance that the company will successfully regain compliance within the cure period.

Risks

• Failure to regain compliance with Nasdaq Listing Rule 5605(b)(1) within the cure period could lead to delisting from the Nasdaq Capital Market.
• The company's stock price could be negatively impacted by the non-compliance issue.

Future Outlook

The company intends to elect an additional Independent Director to the Board as soon as practicable and prior to the expiration of this cure period. However, there can be no assurance that the Company will successfully regain compliance with Nasdaq Listing Rule 5605(b)(1) within the applicable cure period.

Management Comments

• The Company intends to elect an additional Independent Director to the Board as soon as practicable and prior to the expiration of this cure period.

Industry Context

Many companies listed on Nasdaq are required to maintain a majority of independent directors on their boards to ensure good corporate governance and protect shareholder interests. Failure to comply with these requirements can lead to delisting and negatively impact investor confidence.

Comparison to Industry Standards

• Nasdaq Listing Rule 5605(b)(1) is a standard requirement for companies listed on the exchange, ensuring board independence.
• Companies like AquaVenture Holdings (WAAS) and Consolidated Water Co. Ltd. (CWCO), operating in similar water-related industries, are also subject to these listing requirements.
• Compliance with independent director requirements is a common benchmark for corporate governance among publicly traded companies.

Stakeholder Impact

• Shareholders may be concerned about the company's non-compliance with Nasdaq listing rules.
• Employees may experience uncertainty due to the potential impact on the company's stock price and listing status.

Next Steps

• Elect an additional independent director to the Board.
• File the proxy statement for the 2025 Annual Meeting with the SEC.
• Hold the 2025 Annual Meeting of Stockholders on June 11, 2025.

Key Dates

Keywords

Nasdaq, compliance, independent director, listing rule, 374Water Inc., SCWO, annual meeting